Close Menu

More articles about Sample Prep

Overall growth was driven by growth in sequencing instrument and consumables sales, which offset a 24 percent decline in microarray revenues.

10x will pay Becton Dickinson $25 million over four years and the firms have agreed to refrain from engaging in a legal battle on other fronts.

Visium, which provides gene expression information along with spatial information from the same tissue sample, will be shipped later next month.

The startup has developed a platform that allows precise engineering of optical properties to provide high-resolution analysis of single cells by high throughput flow cytometry.

The Irvine, California-based firm said its "Revolution" system offer recovery rates of 70 to 90 percent across a wide range of liquid sample volumes.

The firm will use the funding to build a high-throughput flow cytometry system that sorts cells based on high-content 3D features.

The Boston-based company is working to make its extracellular vesicle detection technology more widely available for research and biomarker discovery.

The firm said CRISPR will enable targeted sequencing of long regions of interest that were previously only accessible with long-read whole-genome sequencing.

10x CEO and Cofounder Serge Saxonov reflected on how the firm's IPO got so big and how he plans to make the single-cell analysis firm even bigger.

The Pleasanton, California-based single-cell sequencing firm said that net proceeds of the IPO will be approximately $357.5 million.

The new method may be useful in future noninvasive prenatal tests that rely on the analysis of DNA from fetal cells instead of cell-free fetal DNA.

The company believes that Xdrop will find adopters in academia and clinical research, although diagnostics is on its radar.

Spurred to develop new microfluidic chip technology, 10x told customers not to worry about the transition but told a court there would be "guaranteed hitches."

The SuperExtract 32 with the SuperExtract Viral Mag NA Purification kit provides high-quality purification of hepatitis and HIV viral nucleic acid.

The company provided updates on its newborn screening testing presence.

Researchers have launched a startup called Fluxus to commercialize a platform based on the optofluidic chip for molecular analysis.

In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.

Researchers developed a microfluidic device that combines antibody-based cell capture and disulfide cleavage for downstream microRNA detection.

The firm will begin a verification study later this month using its cell-sorting platform and molecular analysis tool on patients with a pelvic mass scheduled for surgery.

The Methyl-HiC assay, which combines epigenetic and genome structure analyses, comes from a lab with a history of commercializing tests.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.